Celon Pharma SA CLN

GPW · Poland · Health Technology

PLN 18.700.00 (0.00%)

Market closed· Oct 1, 2026, 3:00 PM UTC· PLN · Data may be delayed

Company news

Yahoo FinanceOct 08, 2025

FDA Clears Celon Pharma’s Schizophrenia Drug for Phase 3 Trial

FDA clears path for Phase 3 testing following positive Type B meetingRegulatory alignment confirms preclinical data sufficient for pivotal initiationPhase 3 to include two 28-day trials and a 12-month safety extensionCPL’36 demonstrated strong efficacy and safety in prior Phase 2 studyProgram expansion planned into additional CNS indications, including Parkinson’s disease WARSAW, Poland, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Celon Pharma S.A. (WSE: CLN) announced today it has secured a key regulator

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.